Cabaletta Bio logo

Cabaletta Bio

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform – encompassing chimeric antigen receptor T cells for autoimmunity (CARTA: CABA-201, a 4-1BB-containing CD19-CAR T) and Cabaletta Bio’s proprietary chimeric autoantibody receptor T cells (CAART: multiple candidates including DSG3-CAART for mucosal pemphigus vulgaris, MuSK-CAART for MuSK myasthenia gravis) – provides multiple opportunities to treat broad and challenging autoimmune diseases. Cabaletta Bio’s headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com.

Free account • No credit card • 5 profiles/day

Biotechnology Research 199 Employees Found Philadelphia, United States Founded 2017 8490 Similar Companies
199 Employees Found
87% Email Coverage
$5.0M Est Revenue
1 Office HQ
8490 Similar Companies
Sep '26 Last Verified

Cabaletta Bio – Company Information

Biotechnology Research
Founded 2017
2929 Arch St, Philadelphia, Pennsylvania, 19104, US
biotech dermatology cell therapy immunology BIOTECH autoimmune Dermatology​ IMMUNOLOGY cell therapy

Frequently asked questions about Cabaletta Bio

What is Cabaletta Bio email format?

The widely used Cabaletta Bio email format is {first_initial}{last} (e.g. jsmith@cabalettabio.com) with 75.00% adoption across the company.

What is Cabaletta Bio customer service number?

To contact Cabaletta Bio customer service number in your country click here to find.

Who is the CEO of Cabaletta Bio?

Steven Nichtberger is the CEO of Cabaletta Bio.

Who are the decision makers in Cabaletta Bio?

The decision makers in Cabaletta Bio are Shawn Tomasello, Gwendolyn Binder, Steven Nichtberger, etc. Click to Find Cabaletta Bio decision makers emails.